Endocrine-Metabolic Dysfunction and Thrombogenicity: Pathophysiological Links to Cardiovascular Risk
DOI:
https://doi.org/10.64784/294Keywords:
endocrine-metabolic disorders, prothrombotic state, cardiovascular risk, diabetes mellitus, obesity, metabolic syndrome, insulin resistance, coagulation, platelet activation, fibrinolysis, endothelial dysfunction, inflammation, atherothrombosisAbstract
Endocrine-metabolic disorders are increasingly recognized as major determinants of cardiovascular risk because their effects extend beyond alterations in glucose and lipid metabolism and involve inflammatory, vascular, and hemostatic pathways. This review analyzed the interaction between endocrine-metabolic abnormalities, the development of a prothrombotic state, and cardiovascular risk, with particular emphasis on obesity, insulin resistance, type 2 diabetes mellitus, metabolic syndrome, thyroid dysfunction, and hypercortisolism. A structured integrative review was conducted using scientific evidence from clinical guidelines, systematic reviews, meta-analyses, mechanistic studies, and epidemiological investigations. The findings showed that obesity, diabetes mellitus, and metabolic syndrome presented the greatest overlap of pathophysiological mechanisms, particularly chronic inflammation, oxidative stress, endothelial dysfunction, platelet hyperreactivity, coagulation activation, and impaired fibrinolysis. Coagulation activation was one of the most consistently identified pathways, while reduced fibrinolytic capacity, frequently associated with increased plasminogen activator inhibitor-1 activity, contributed to thrombus persistence. Diabetes was additionally associated with structural alterations of fibrin and increased platelet responsiveness, whereas visceral adiposity was linked to inflammatory and procoagulant signaling. Thyroid dysfunction and hypercortisolism also demonstrated relevant hemostatic alterations, supporting the broader relationship between endocrine regulation and thrombosis. Overall, the evidence indicates that cardiovascular risk in endocrine-metabolic disease results from an interconnected network in which metabolic dysfunction promotes inflammation and oxidative stress, followed by endothelial injury, platelet and coagulation activation, impaired fibrinolysis, and ultimately atherothrombotic events. The prothrombotic state therefore represents an important intermediate pathophysiological phenotype between endocrine-metabolic dysfunction and cardiovascular disease. These findings support comprehensive cardiovascular prevention and highlight the need for future studies evaluating integrated metabolic and hemostatic biomarkers for improved risk stratification.
References
[1] S. M. Grundy et al., “Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement,” Circulation, vol. 112, no. 17, pp. 2735–2752, 2005, doi: 10.1161/CIRCULATIONAHA.105.169404.
[2] K. G. M. M. Alberti et al., “Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity,” Circulation, vol. 120, no. 16, pp. 1640–1645, 2009, doi: 10.1161/CIRCULATIONAHA.109.192644.
[3] R. Kahn, J. Buse, E. Ferrannini, and M. Stern, “The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes,” Diabetes Care, vol. 28, no. 9, pp. 2289–2304, 2005, doi: 10.2337/diacare.28.9.2289.
[4] P. J. Grant, “Diabetes mellitus as a prothrombotic condition,” J. Intern. Med., vol. 262, no. 2, pp. 157–172, 2007, doi: 10.1111/j.1365-2796.2007.01824.x.
[5] N. Vazzana, P. Ranalli, C. Cuccurullo, and G. Davì, “Diabetes mellitus and thrombosis,” Thromb. Res., vol. 129, no. 3, pp. 371–377, 2012, doi: 10.1016/j.thromres.2011.11.052.
[6] C. P. Domingueti, L. M. S. A. Dusse, M. G. Carvalho, L. P. de Sousa, K. B. Gomes, and A. P. Fernandes, “Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications,” J. Diabetes Complications, vol. 30, no. 4, pp. 738–745, 2016, doi: 10.1016/j.jdiacomp.2015.12.018.
[7] A. I. S. Sobczak and A. J. Stewart, “Coagulatory defects in type-1 and type-2 diabetes,” Int. J. Mol. Sci., vol. 20, no. 24, Art. no. 6345, 2019, doi: 10.3390/ijms20246345.
[8] F. Santilli, N. Vazzana, R. Liani, M. T. Guagnano, and G. Davì, “Platelet activation in obesity and metabolic syndrome,” Obes. Rev., vol. 13, no. 1, pp. 27–42, 2012, doi: 10.1111/j.1467-789X.2011.00930.x.
[9] P.-E. Morange and M.-C. Alessi, “Thrombosis in central obesity and metabolic syndrome: Mechanisms and epidemiology,” Thromb. Haemost., vol. 110, no. 4, pp. 669–680, 2013, doi: 10.1160/TH13-01-0075.
[10] F. Samad and W. Ruf, “Inflammation, obesity, and thrombosis,” Blood, vol. 122, no. 20, pp. 3415–3422, 2013, doi: 10.1182/blood-2013-05-427708.
[11] I. O. Blokhin and S. R. Lentz, “Mechanisms of thrombosis in obesity,” Curr. Opin. Hematol., vol. 20, no. 5, pp. 437–444, 2013, doi: 10.1097/MOH.0b013e3283634443.
[12] K. A. L. Darvall, R. C. Sam, S. H. Silverman, A. W. Bradbury, and D. J. Adam, “Obesity and thrombosis,” Eur. J. Vasc. Endovasc. Surg., vol. 33, no. 2, pp. 223–233, 2007, doi: 10.1016/j.ejvs.2006.10.006.
[13] G. Vilahur, S. Ben-Aicha, and L. Badimon, “New insights into the role of adipose tissue in thrombosis,” Cardiovasc. Res., vol. 113, no. 9, pp. 1046–1054, 2017, doi: 10.1093/cvr/cvx086.
[14] G. S. Hotamisligil, “Inflammation and metabolic disorders,” Nature, vol. 444, no. 7121, pp. 860–867, 2006, doi: 10.1038/nature05485.
[15] T. M. Powell-Wiley et al., “Obesity and cardiovascular disease: A scientific statement from the American Heart Association,” Circulation, vol. 143, no. 21, pp. e984–e1010, 2021, doi: 10.1161/CIR.0000000000000973.
[16] Emerging Risk Factors Collaboration, “Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies,” Lancet, vol. 375, no. 9733, pp. 2215–2222, 2010, doi: 10.1016/S0140-6736(10)60484-9.
[17] A. Squizzato, E. Romualdi, H. R. Büller, and V. E. A. Gerdes, “Thyroid dysfunction and effects on coagulation and fibrinolysis: A systematic review,” J. Clin. Endocrinol. Metab., vol. 92, no. 7, pp. 2415–2420, 2007, doi: 10.1210/jc.2007-0199.
[18] R. van der Pas, F. W. G. Leebeek, L. J. Hofland, W. W. de Herder, and R. A. Feelders, “Hypercoagulability in Cushing’s syndrome: Prevalence, pathogenesis and treatment,” Clin. Endocrinol. (Oxf.), vol. 78, no. 4, pp. 481–488, 2013, doi: 10.1111/cen.12094.
[19] N. Marx et al., “2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes,” Eur. Heart J., vol. 44, no. 39, pp. 4043–4140, 2023, doi: 10.1093/eurheartj/ehad192.
[20] R. Ross, “Atherosclerosis—An inflammatory disease,” N. Engl. J. Med., vol. 340, no. 2, pp. 115–126, 1999, doi: 10.1056/NEJM199901143400207.
